Patricio Escalante

Patricio Escalante

Auto-generated profile, based on publicly available information

Patricio Escalante

Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, Mayo Clinic, United States

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Chest
Verified
Journal Article
Open access
RIRichard S. Irwin
Richard S. Irwin
NDNatasha Dudiki
Natasha Dudiki
CFCynthia L. French
Cynthia L. French
ADAbd Moain Abu Dabrh
Abd Moain Abu Dabrh
KAKenneth Altman
Kenneth Altman
AVAnne E. Vertigan
Anne E. Vertigan
To update the section on complications associated with coughing in the 2006 CHEST cough guidelines to address 2 aims: systematically identify and thematically categorize the diverse complications of cough providing a guide for future studies and identify gaps in the literature for future research. To guide our literature search, we asked the following key clinical question: What are the potential complications associated with the act of coughing that have been reported in infants, children, adolescents and adults? A scoping review was performed using PubMed and SCOPUS databases that were searched from their beginning until September 6, 2019. 247 publications met our inclusion criteria. To these, we added 38 articles from the 2006 complications paper not identified in the literature search plus the paper itself for a final total of 286 publications that formed the basis of this review. Since 2006, 3 new categories of complications have been reported: ear, nose and throat; disease transmission; and laboratory testing. Multiple additional complications that fall outside of these 3 categories have also been identified and included in the following categories: cardiovascular, constitutional symptoms, dermatological, gastrointestinal, genitourinary, musculoskeletal, neurological, ophthalmological, psychosocial/quality of life, and respiratory. Not previously highlighted is that some of the complications led to serious morbidity including death, especially in patients with comorbid conditions and potentially resulted in harm to others when cough resulted in a motor vehicle accident. Our work identified a large number of cough complications that we thematically categorized primarily by organ system so that future studies of each system or each complication can be conducted. The gap in the literature that future studies should address is to identify the frequency of the complications and the strength of their association with cough. Only then will one be able to describe the findings in a manner that allows specific recommendations for avoiding these complications. In the meantime, patients with cough should be evaluated and managed according to evidence-based guidelines to mitigate or prevent the myriad of potential complications associated with coughing.

15 October 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HRHeather M. Robison
Heather M. Robison
CCCole A. Chapman
Cole A. Chapman
HZHaowen Zhou
Haowen Zhou
CECourtney L. Erskine
Courtney L. Erskine
ETElitza Theel
Elitza Theel
PEPatricio Escalante
Patricio Escalante
Accurate detection and risk stratification of latent tuberculosis infection (LTBI) remains a major clinical and public health problem. We hypothesize that multiparameter strategies that probe immune responses to Mycobacterium tuberculosis can provide new diagnostic insights into not only the status of LTBI infection, but also the risk of reactivation. After the initial proof-of-concept study, we developed a 13-plex immunoassay panel to profile cytokine release from peripheral blood mononuclear cells stimulated separately with Mtb-relevant and non-specific antigens to identify putative biomarker signatures. We sequentially enrolled 65 subjects with various risk of TB exposure, including 32 subjects with diagnosis of LTBI. Random Forest feature selection and statistical data reduction methods were applied to determine cytokine levels across different normalized stimulation conditions. Receiver Operator Characteristic (ROC) analysis for full and reduced feature sets revealed differences in biomarkers signatures for LTBI status and reactivation risk designations. The reduced set for increased risk included IP-10, IL-2, IFN-γ, TNF-α, IL-15, IL-17, CCL3, and CCL8 under varying normalized stimulation conditions. ROC curves determined predictive accuracies of > 80% for both LTBI diagnosis and increased risk designations. Our study findings suggest that a multiparameter diagnostic approach to detect normalized cytokine biomarker signatures might improve risk stratification in LTBI.

1 September 2015 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
PEPatricio Escalante
Patricio Escalante
TPTobias Peikert
Tobias Peikert
VKVirginia P. Van Keulen
Virginia P. Van Keulen
CECourtney L. Erskine
Courtney L. Erskine
CBCathy L. Bornhorst
Cathy L. Bornhorst
ALAndrew H. Limper
Andrew H. Limper
Rationale: Most immunocompetent patients diagnosed with latent tuberculosis infection (LTBI) will not progress to tuberculosis (TB) reactivation. However, current diagnostic tools cannot reliably distinguish nonprogressing from progressing patients a priori, and thus LTBI therapy must be prescribed with suboptimal patient specificity. We hypothesized that LTBI diagnostics could be improved by generating immunomarker profiles capable of categorizing distinct patient subsets by a combinatorial immunoassay approach. Objectives: A combinatorial immunoassay analysis was applied to identify potential immunomarker combinations that distinguish among unexposed subjects, untreated patients with LTBI, and treated patients with LTBI and to differentiate risk of reactivation. Methods: IFN-γ release assay (IGRA) was combined with a flow cytometric assay that detects induction of CD25+CD134+ coexpression on TB antigen–stimulated T cells from peripheral blood. The combinatorial immunoassay analysis was based on receiver operating characteristic curves, technical cut-offs, 95% bivariate normal density ellipse prediction, and statistical analysis. Risk of reactivation was estimated with a prediction formula. Measurements and Main Results: Sixty-five out of 150 subjects were included. The combinatorial immunoassay approach identified at least four different T-cell subsets. The representation of these immune phenotypes was more heterogeneous in untreated patients with LTBI than in treated patients with LTBI or unexposed groups. Patients with IGRA(+) CD4+CD25+CD134+ T-cell phenotypes had the highest estimated reactivation risk (4.11 ± 2.11%). Conclusions: These findings suggest that immune phenotypes defined by combinatorial assays may potentially have a role in identifying those at risk of developing TB; this potential role is supported by risk of reactivation modeling. Prospective studies will be needed to test this novel approach.

1 January 2019 in Integrative Biology
Verified
Journal Article
Closed access
PDF file
HRHeather M Robison
Heather M Robison
PEPatricio Escalante
Patricio Escalante
EVEnrique Valera
Enrique Valera
CECourtney L Erskine
Courtney L Erskine
LALoretta Auvil
Loretta Auvil
RBRyan C Bailey
Ryan C Bailey
Latent tuberculosis infection (LTBI) is estimated in nearly one quarter of the world’s population, and of those immunocompetent and infected ~10% will proceed to active tuberculosis (TB). Current diagnostics cannot definitively identify LTBI and provide no insight into reactivation risk, thereby defining an unmet diagnostic challenge of incredible global significance. We introduce a new machine-learning-driven approach to LTBI diagnostics that leverages a high throughput, multiplexed cytokine detection technology and powerful bioinformatics to reveal multi-marker signatures for LTBI diagnosis and risk stratification. This approach is enabled through an individualized normalization procedure that allows disease-relevant biomarker signatures to be revealed despite heterogeneity in basal immune response. Specifically, cytokines secreted from antigen-challenged peripheral blood mononuclear cells were detected using silicon photonic sensor arrays and multidimensional data correlation of individually-normalized immune responses revealed signatures important for LTBI status. These results demonstrate a powerful combination of multiplexed biomarker detection technologies, precision immune normalization, and feature selection algorithms that revealed positively correlated multi-biomarker signatures for LTBI status and reactivation risk stratification from a relatively simple blood-based assay.

1 December 2018 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
MAMiguel Arias-Guillén
Miguel Arias-Guillén
MMMarta M. Sánchez Menéndez
Marta M. Sánchez Menéndez
MAMercedes Alperi
Mercedes Alperi
SRSabino Riestra
Sabino Riestra
MBMaría Teresa González Budiño
María Teresa González Budiño
PEPatricio Escalante
Patricio Escalante

26 April 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
GRGuilherme P Ramos
Guilherme P Ramos
GSGregory Stroh
Gregory Stroh
BABadr Al-Bawardy
Badr Al-Bawardy
WFWilliam A Faubion
William A Faubion
KPKonstantinos A Papadakis
Konstantinos A Papadakis
PEPatricio Escalante
Patricio Escalante
Treatment for latent tuberculosis infection (LTBI) is of particular concern in patients with inflammatory bowel disease (IBD) initiating biologic therapies to prevent tuberculosis (TB) reactivation. This study aimed to evaluate the effectiveness of LTBI treatment in IBD patients receiving biologic therapy. There was a retrospective review of all IBD patients diagnosed with LTBI following a tuberculin skin test (TST) and/or interferon gamma release assay (IGRA) and who received biologic therapy between 2002 and 2016. The primary outcome was tuberculosis reactivation after completion of LTBI treatment. Three-hundred twenty-nine IBD patients were identified, and 35 (27 Crohn’s disease; 8 ulcerative colitis) met the study inclusion criteria. The mean age was 38.3 years, and 68.6% were male. The most common LTBI treatment regimen was isoniazid (INH) for 9 months (74%). Biologic therapies used were infliximab (40%), adalimumab (29%), vedolizumab (20%), and certolizumab pegol (11%). Combination therapy with an immunomodulator was administered in 57% of cases. The median time from initiation of LTBI treatment to biologics was 43 days. The mean duration of follow-up was 2.9 years. The estimated median annual risk of TB reactivation without treatment was 0.52% by a prediction formula. Only 1 patient taking adalimumab monotherapy developed reactivation of TB several years after completing 6 months of isoniazid therapy. The estimated TB reactivation rate was 0.98 cases per 100 patient-years of follow-up in our cohort. Treatment for LTBI in patients with IBD treated with biologics is effective but does not eliminate the risk of reactivation.